Skip to main
A plain-English orientation to the most-studied research peptides across tissue repair, the growth-hormone axis, metabolic, longevity, immune and cognitive research — what each one is, how it works, and what the literature actually shows.
Your Peptide Tracker

FILE 02 / ESTABLISHED HUMAN EVIDENCE

Semaglutide: One Receptor, A Wide Trial Record

How a long-acting GLP-1 signal connects appetite and glucose biology with large cardiovascular, kidney and weight studies.

Start here

Semaglutide is a peptide medicine that copies one of the body’s meal signals, GLP-1. It activates the GLP-1 receptor, helping the pancreas respond to glucose, reducing inappropriate glucagon release, slowing stomach emptying and changing appetite signaling. The molecule was modified so it lasts much longer than natural GLP-1.

Its evidence file differs from the other entries in this hub. Manufactured semaglutide is approved for specific medical uses and has been tested in large human outcome trials. Research includes body-weight, cardiovascular and kidney endpoints [9][10][11]. That does not make every online claim accurate, and it does not erase known gastrointestinal and biliary risks [12]. This page keeps the distinction between a medicine’s published evidence, its approved context and anecdotal discussion. It describes the record without offering individual treatment or dosing guidance.

What it is

Semaglutide is a thirty-one-amino-acid analogue of human GLP-1. Small changes to its backbone help it resist rapid enzyme breakdown, while a fatty side chain promotes reversible binding to albumin. Natural GLP-1 disappears quickly; the engineered form circulates long enough to support extended action [12]. Ozempic, Wegovy and Rybelsus are brand names for approved semaglutide products in different indications or formulations; the names do not make the formulations interchangeable.

The useful tracking label is “approved GLP-1 receptor agonist with a mature human trial record.” It is still a peptide research subject because investigators continue to study outcomes, mechanisms, formulations and safety across different populations.

What it is

How one receptor reaches several systems

The GLP-1 receptor appears in several parts of the metabolic control network. In pancreatic beta cells, activation strengthens insulin secretion when glucose is elevated. In alpha cells, it reduces inappropriate glucagon signaling. Messages traveling through the gut, vagal pathways, brainstem and hypothalamus influence meal termination and appetite. Slower gastric emptying also changes how quickly nutrients arrive.

An analogy helps: semaglutide uses one key, but copies of that lock sit in several rooms. The response depends on the room. This is different from retatrutide, which carries activity at three receptor families. A broader target list is not automatically better; head-to-head and outcome trials are needed to compare actual effects.

What the research shows

The STEP 1 randomized trial enrolled 1,961 adults with overweight or obesity without diabetes. At week 68, the semaglutide study group had a mean body-weight change of −14.9%, compared with −2.4% for placebo [11]. A later head-to-head obesity trial enrolled 751 adults and reported mean change of −13.7% with semaglutide and −20.2% with tirzepatide at week 72 [8]. That comparison concerns the trial regimens and population; it is not a universal ranking.

The outcome record extends beyond weight. SELECT followed 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes. Major adverse cardiovascular events were lower in the semaglutide group, with a hazard ratio of 0.80 and a 95% confidence interval from 0.72 to 0.90 [10]. FLOW enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Its major kidney-disease composite produced a hazard ratio of 0.76, with a 95% confidence interval from 0.66 to 0.88 [9]. These large trials are why semaglutide occupies a more mature evidence tier in this collection.

Reported effects, cautions and safety

Community reports are anecdotal, not clinical evidence. Posters frequently describe reduced appetite, quieter food thoughts, fewer cravings and weight change. Nausea, bowel changes, belching and fatigue are also common themes, while reflux, taste changes, dizziness, hair shedding and facial changes appear less consistently. Such posts can reveal questions worth studying, but they do not verify a product, regimen or cause.

A dedicated safety review found that gastrointestinal effects were usually mild to moderate and transient, with nausea reported in roughly one-third of patients across the reviewed evidence [12]. The review also identified increased biliary-disease risk and noted that pancreatic and thyroid-cancer signals remained too uncommon for definitive conclusions [12]. Safety depends on population, medical history, formulation and supervision. The evidence attached to approved manufactured products does not automatically transfer to compounded or unverified material.

Where it fits in the tracker

Semaglutide is the anchor for what a developed evidence trail looks like: mechanistic work, randomized efficacy trials, large outcomes trials, regulatory decisions and continued safety monitoring. It provides a benchmark for reading retatrutide’s earlier-stage human program and exposes the much larger gap between human outcomes research and the mostly preclinical records for KPV and MOTS-c.

Tracking does not stop at approval. New studies can expand an indication, clarify who was represented, refine risk estimates or compare another agent directly. The semaglutide file therefore remains active, but its current evidence maturity should not be blurred with the exploratory status of the other compounds.